GLP-1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: A systematic review and meta-analysis

Thomas Karagiannis,Apostolos Tsapas,Eleni Athanasiadou,Ioannis Avgerinos,Aris Liakos,David R. Matthews,Eleni Bekiari

Diabetes Research and Clinical Practice（2021）

引用 0|浏览0

暂无评分

摘要

•In patients ≥65 years, GLP-1 RAs reduced atherosclerotic oucomes.•In patients ≥65 years, SGLT2 inhibitors reduced heart failure and renal outcomes.•Some benefits were more pronounced in older patients compared to those <65 years.•Results for patients ≥75 years were based on limited data from primary studies.

查看译文

关键词

Type 2 diabetes,Older adults,Cardiovascular outcomes,Heart failure,Renal outcomes,Meta-analysis

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要